LifeVantage (LFVN) Corporation announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration. In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP and SST were thoroughly examined. All 14 peptides were influenced in the desired direction, with key results including: GRP: +1,087% increase; TFF3: +116% increase; VIP: +100% increase; OXM: +77% increase; CCK: +69% increase.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFVN:
- LifeVantage Corp’s Earnings Call Highlights Strategic Growth
- LifeVantage price target lowered to $12 from $30 at Lake Street
- LifeVantage Reports Modest Revenue Growth in Q1 2026
- LifeVantage reaffirms FY26 EPS outlook $1.00-$1.15, consensus $1.01
- LifeVantage reports Q1 adjusted EPS 18c, two estimates 19c